Clinical trial · Observational
Long-term Safety and Efficacy of GBG Study Participants
Registry for Long-term Follow-up of Safety and Efficacy Parameters of GBG Study Participants
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
The ETERNITY study is an international, multicenter, observational study that aims to follow up patients who have participated in a GBG trial for early breast cancer, even after the study has officially ended, in order to collect long-term data on survival, late or delayed adverse events, in addition to information related to pregnancy, fertility and other parameters impacting quality of life.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- Disease-free survival (DFS)
- timeFrame
- 10 years
- description
- Time period between randomization and first event (ipsi- or contralateral (non-) in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast))
- measure
- Invasive disease-free survival (iDFS)
- timeFrame
- 10 years
- description
- Time period between randomization and first event (ipsi- or contralateral invasive in-breast or loco-regional recurrence, distant recurrence, death from breast cancer, death from non-breast cancer cause, death from unknown cause, invasive contralateral breast cancer, second primary invasive cancer (non-breast))
- measure
- Distant disease-free survival (DDFS)
- timeFrame
- 10 years
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: * Participation and treatment in a GBG clinical trial for early breast cancer. * Prospective registration: Written informed consent according to local regulatory requirements prior to data and biomaterial collection. Exclusion criteria: * Participation and treatment in a non-GBG clinical trial for early breast cancer. * Patients with advanced or metastatic breast cancer who have participated and received treatment in a GBG clinical trial.
References
Publications (0)
Data not yet available